tradingkey.logo

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System

ReutersApr 3, 2025 9:03 PM

- Sangamo Therapeutics Inc SGMO.O:

  • SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM

  • SANGAMO THERAPEUTICS INC: SANGAMO TO RECEIVE AN $18 MILLION UPFRONT LICENSE FEE

  • SANGAMO THERAPEUTICS INC: ELIGIBLE TO EARN UP TO $1.4 BILLION IN ADDITIONAL LICENSED TARGET FEES AND MILESTONE PAYMENTS

  • SANGAMO: AGREEMENT GRANTS LILLY RIGHTS TO EMPLOY CO'S NOVEL PROPRIETARY CAPSID, STAC-BBB, FOR UP TO 5 POTENTIAL DISEASE TARGETS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI